Search Results

Showing 107 results

Taxonomy / Categories

GCLLSG 2026

Congress Year

German CLL Studygroup

iwCLL 2025

Congress Year

International Workshop on CLL 2025

CLL

Disease Area

CLL/SLL

Disease Area

CLL

Congress Disease State

CLL/SLL

Congress Disease State

R/R CLL

Congress Disease State

Treatment Naive CLL/SLL

Congress Disease State

Satellite Symposium – The human side of CLL therapy: Shared decisions, patient preference and psychological outcomes

Congress Resource

Beone at ash 2025 CLL

Page

Updates on zanubrutinib monotherapy in high-risk, treatment-naïve (TN) CLL from the SEQUOIA study.1 These long-term results continue to support zanubrutinib as an effective, tolerable frontline option for CLL, including in those with high-risk features.1 Zanubrutinib in R/R CLL Long-term extension from the Phase 3 ALPINE study continues to demonstrate sustained PFS benefit and response rates regardless of del(17p) status.2 With up to 6 years of follow-up, patients with del(17p) treated with zanubrutinib demonstrated sustained efficacy comparable with the overall population, along with a similar safety profile.2 This communication may include descriptions of products or uses that are not approved by the local Authorities.

Real-world impact of atrial fibrillation (AFib) on cardiovascular (CV) outcomes and healthcare resource utilization (HCRU) in patients with chronic lymphocytic leukemia (CLL)

Congress Resource

Treatment burden among patients (pts) aged 75 or older with chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL)

Congress Resource

Real-world comparative analysis of treatment discontinuation with covalent Bruton tyrosine kinase inhibitors in first-line chronic lymphocytic leukemia (CLL)

Congress Resource

Real-world zanubrutinib treatment patterns in CLL/SLL among US community oncology patients with prior acalabrutinib therapy

Congress Resource

A longitudinal analysis of patients with CLL/SLL with impaired health-related quality of life scores at baseline who were treated with zanubrutinib versus ibrutinib: A post hoc analysis of ALPINE

Congress Resource

Zanubrutinib vs ibrutinib in treatment-naive chronic lymphocytic leukemia (CLL): Implications for interpreting fixed-duration treatment outcomes from CLL17

Congress Resource

Long-term follow-up for safety and efficacy of zanubrutinib in elderly (≥80 Years) treatment‑naïve CLL/SLL patients, including those with del(17p): Subgroup analysis from the SEQUOIA trial

Congress Resource

First-line treatment of CLL/SLL with the all-oral combination of sonrotoclax and zanubrutinib achieves undetectable minimal residual disease rates of >90%, including in patients with del(17p)/TP53

Congress Resource

You are now leaving the website

This link is provided for information purposes only. You’ll be leaving beonemedaffairs.com and accessing a third-party website over which [BeOne Medicines | GmbH] has no control or influence.

This link will take you to a third-party website outside of beonemedaffairs.com.

[BeOne Medicines | GmbH] has no control over this website and makes no representations regarding its content or availability in your location. [BeOne Medicines | GmbH] declines any responsibility for third-party information, data usage policies, or personal data processing.

By proceeding, you acknowledge that you are part of the intended audience of the third-party website and confirm your compliance with applicable laws.

Do you want to leave beonemedaffairs.com

You are now leaving the the website beonemedaffairs.com and entering another BeOne website with different terms of use. Information included on this website may not be specific to your country. Click Continue to proceed